Cel-Sci

Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases

All edits

Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
July 2018
Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
4,478,000
Edits on 12 Mar, 2020
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 12 Mar, 2020
Edits made to:
Article (+16/-16 characters)
Article

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases. The company was founded in 1983 by Maximilian de Clara, in Vienna, VirginiaVienna, Virginia, United States.

Daniel Frumkin"added description, article, company, further reading, people, infobox items, "
Daniel Frumkin edited on 12 Mar, 2020
Edits made to:
Description (+129 characters)
Article (+1062 characters)
People (+3 rows) (+6 cells) (+70 characters)
Further reading (+6 rows) (+19 cells) (+790 characters)
Companies (+1 rows) (+4 cells) (+83 characters)
Categories (+3 topics)
Related Topics (+2 topics)
Topic thumbnail

Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases

Article

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases. The company was founded in 1983 by Maximilian de Clara, in Vienna, Virginia, United States.

The company looks to deal with clinical phases of head and neck cancer. Their theory is to boost the immune system before turning to options such as surgery, radiation, and chemotherapy.

COVID-19

The company has began developing an immunotherapy solution for the potential to treat patients with COVID-19. The outbreak of the coronavirus has prompted Cel-Sci to provide their peptide technology LEAPS which stimulates protective cell mediated T-cell responses and reduce viral loads. The technology can be used to build peptides that exhibit both antiviral and anti-inflammatory properties. LEAPS is designed to target the infectious virus, and also start the appropriate protective response to it.

LEAPS is a peptide-based medicine that can help reduce tissue damage caused by lung infections, which is a mortality issue for elderly patients.

People

Name
Role
LinkedIn

Eyal Talor

CSO

Geert R. Kersten

CEO

Maximilian de Clara

President, Director

Companies

Company
CEO
Location
Products/Services

CEL-SCI

Geert Kersten

Vienna, Virginia, United States

Therapeutics and pharmaceuticals

Further reading

Title
Author
Link
Type
Date

Cel Sci - Cel Sci Corp

Web

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

Web

March 11, 2020

Coronavirus outbreak: Top coronavirus drugs and vaccines in development

Web

March 11, 2020

US biotech CEL-SCI Corporation has announced that it is developing an immunotherapy with the potential...

The Pharma Letter

Web

US biotech CEL-SCI Corporation has announced that it is developing an immunotherapy with the potential...

The Pharma Letter

Web

Categories
Related Topics
Edits on 8 Sep, 2019
Golden AI
Golden AI edited on 8 Sep, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
CEL SCI CORP funding round, July 2018
Kristoffer Carlo Aguirre
Kristoffer Carlo Aguirre approved a suggestion from Golden's AI on 8 Sep, 2019
Edits made to:
Infobox (+7 properties)
Infobox
SIC code
2,836
CIK number
725,363
IRS number
840,916,344
Headquarters
Virginia
Place of incorporation
Colorado
Stock symbol
CVM
Stock exchange
NYSE MKT
Edits on 9 Jul, 2019
Golden AI"Remove default description"
Golden AI edited on 9 Jul, 2019
Edits made to:
Description (-7 characters)
Topic thumbnail

Cel-Sci

Company

Edits on 12 Jun, 2019
Golden AI
Golden AI edited on 12 Jun, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
Cel-Sci funding round, August 2009
Edits on 27 Apr, 2019
Umair Shah"Approved suggestion from source: http://www.cel-sci.com"
Umair Shah approved a suggestion from Golden's AI on 27 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Julius John Villarisco"Approved suggestion from source: http://www.cel-sci.com"
Julius John Villarisco approved a suggestion from Golden's AI on 27 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 26 Apr, 2019
Henry Ogolla"Approved suggestion from source: http://www.cel-sci.com"
Henry Ogolla approved a suggestion from Golden's AI on 26 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 17 Apr, 2019
Golden AI
Golden AI edited on 17 Apr, 2019
Edits made to:
Description (+7 characters)
Topic thumbnail

Cel-Sci

Company

Edits on 6 Apr, 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 6 Apr, 2019
Edits made to:
Infobox (+3 properties)
Topic thumbnail

Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases

Infobox
Industry
Biotechnology
Edits on 7 Mar, 2019
Golden AI
Golden AI edited on 7 Mar, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Company
Edits on 5 Mar, 2019
Rebecca Hammond
Rebecca Hammond approved a suggestion from Golden's AI on 5 Mar, 2019
Edits made to:
Infobox (+2 properties)
Infobox
Location
Vienna, Virginia
Rebecca Hammond"Initial topic creation"
Rebecca Hammond created this topic on 5 Mar, 2019
Edits made to:
Topic thumbnail

 Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.